164 related articles for article (PubMed ID: 32561594)
1. Influence of Zuojin Pill on the Metabolism of Venlafaxine in Vitro and in Rats and Associated Herb-Drug Interaction.
Li Y; Li J; Yan D; Wang Q; Jin J; Tan B; Qiu F
Drug Metab Dispos; 2020 Oct; 48(10):1044-1052. PubMed ID: 32561594
[TBL] [Abstract][Full Text] [Related]
2. Effects of Zuojin Pill (Rhizoma Coptidis and Fructus Evodiae preparation) on the pharmacokinetics and side effects of venlafaxine in humans.
Yan D; Wu M; Hu W; Li Y; Jin J; Yan S; Zhu W; Ye C; Liu J; Liu G; Tan B
Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):522-530. PubMed ID: 35132786
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
5. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
6. Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.
Qiu F; Liu S; Miao P; Zeng J; Zhu L; Zhao T; Ye Y; Jiang J
Eur J Clin Pharmacol; 2016 Jun; 72(6):689-95. PubMed ID: 27023460
[TBL] [Abstract][Full Text] [Related]
7. How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.
Augustin M; Schoretsanitis G; Gründer G; Haen E; Paulzen M
J Clin Psychopharmacol; 2018 Oct; 38(5):498-501. PubMed ID: 30102628
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
9. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro.
Zhan YY; Liang BQ; Gu EM; Hu XX; Lin D; Hu GX; Zheng ZQ
Pharmacology; 2015; 96(3-4):118-23. PubMed ID: 26202346
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.
Shen C; Yang H; Shao W; Zheng L; Zhang W; Xie H; Jiang X; Wang L
Pharm Res; 2024 Apr; 41(4):731-749. PubMed ID: 38443631
[TBL] [Abstract][Full Text] [Related]
13. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
14. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
16. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
18. The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation.
Chen N; Yang XY; Guo CE; Bi XN; Chen JH; Chen HY; Li HP; Lin HY; Zhang YJ
Drug Des Devel Ther; 2018; 12():57-65. PubMed ID: 29343943
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
